Company CVAbout Mankind Pharma Ltd 
Mankind Pharma Ltd
Large Cap
Pharmaceuticals & Biotechnology
Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name "Mankind Pharma Private Limited", by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to "Mankind Pharma Limited" and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.
Company Coordinates
No Company Details Available
Capital StructureCapital Structure
Present Equity Capital
INR 40.06 Cr
Number of Shares
40.06 Cr
Face Value
INR 1.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
14-Aug-2024
40.06
40.06
9000
1
Issued under ESOP Scheme
10-May-2024
40.06
40.06
46698
1
Issued under ESOP Scheme
01-Jun-2017
40.06
40.06
400588440
1
As Per Prospectus
01-Jun-2017
40.06
40.06
200294220
1
Bonus Issue
20-Apr-2017
20.03
20.03
180264798
1
Stock Split
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 32 Schemes (7.78%)
FIIs
Held by 557 FIIs (12.84%)
Promoter with highest holding
Ramesh Juneja Family Trust (held In The Name Of Ramesh Juneja, Managing Trustee) (20.2%)
Highest Public shareholder
Government Pension Fund Global (1.63%)
Individual Investors Holdings
1.36%
Board of Directors
Management
Designation
Remuneration
RAMESH CHAND JUNEJA
Chairman & Wholetime Director
25.93 cr
RAJEEV JUNEJA
Vice Chairman & M.D.
28.88 cr
SHEETAL ARORA
Whole Time Director & CEO
15.46 cr
TILOKCHAND PUNAMCHAND OSTWAL
Independent Director
40.0 lacs
Pradeep Chugh
Company Sec. & Compli. Officer
0
Bharat Anand
Independent Director
24.0 lacs
SATISH KUMAR SHARMA
Whole-time Director
81.2 lacs
Vivek Kalra
Independent Director
27.4 lacs
Vijaya Sampath
Independent Director
32.4 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
No Data Available for Finished Goods Segmentation
No Data Available
Stock DNARevenue and Profits:
Net Sales:
3,697 Cr
(Quarterly Results - Sep 2025)
Net Profit:
512 Cr
Pharmaceuticals & Biotechnology
INR 90,887 Cr (Large Cap)
52.00
34
0.05%
0.34
11.44%
5.97
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
